AI English summary of an SEC filing — figures as filed
Biogen BIIBBiogen said it reported total revenue of $2,386 million for Q4 2023 ($2,544 million a year earlier), GAAP diluted EPS of $1.71, and Non-GAAP diluted EPS of $2.95. For the full year, total revenue was $9,836 million, GAAP diluted EPS was $7.97, and Non-GAAP diluted EPS was $14.72.
Key points
AI summaryBiogen said it reported total revenue of $2,386 million for Q4 2023 ($2,544 million a year earlier), GAAP diluted EPS of $1.71, and Non-GAAP diluted EPS of $2.95. For the full year, total revenue was $9,836 million, GAAP diluted EPS was $7.97, and Non-GAAP diluted EPS was $14.72.
Biogen's multiple sclerosis product revenue for Q4 was $1,168 million, down from $1,269 million a year earlier, and rare disease revenue was $472 million ($459 million a year earlier). Full-year multiple sclerosis product revenue was $4,662 million ($5,430 million a year earlier).
The company said its net cash flow from operations for the full year 2023 was approximately $1.5 billion and free cash flow was approximately $1.3 billion. Operating cash flow includes a payment of approximately $393 million related to Reata. As of December 31, 2023, Biogen had cash and cash equivalents of approximately $1.0 billion, total debt of approximately $6.9 billion, and net debt of approximately $5.9 billion.
Biogen said it expects Non-GAAP diluted EPS for the full year 2024 of $15.00 to $16.00. It expects total revenue to decline by a low- to mid-single digit percentage versus 2023 and operating income to grow by a low-double digit percentage, and it assumed that foreign exchange rates as of February 9, 2024 will remain in effect for the rest of the year.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Biogen Reports Q4 2023 and Full-Year Revenue and EPS
Biogen said it reported total revenue of $2,386 million for Q4 2023 ($2,544 million a year earlier), GAAP diluted EPS of $1.71, and Non-GAAP diluted EPS of $2.95. For the full year, total revenue was $9,836 million, GAAP diluted EPS was $7.97, and Non-GAAP diluted EPS was $14.72.
Source · Based on the filing body and exhibits
Multiple Sclerosis Revenue Decline and Rare Disease Revenue
Biogen's multiple sclerosis product revenue for Q4 was $1,168 million, down from $1,269 million a year earlier, and rare disease revenue was $472 million ($459 million a year earlier). Full-year multiple sclerosis product revenue was $4,662 million ($5,430 million a year earlier).
Source · Based on the filing body and exhibits
Cash Flow and Net Debt
The company said its net cash flow from operations for the full year 2023 was approximately $1.5 billion and free cash flow was approximately $1.3 billion. Operating cash flow includes a payment of approximately $393 million related to Reata. As of December 31, 2023, Biogen had cash and cash equivalents of approximately $1.0 billion, total debt of approximately $6.9 billion, and net debt of approximately $5.9 billion.
Source · Based on the filing body and exhibits
Full-Year 2024 Outlook (Guidance)
Biogen said it expects Non-GAAP diluted EPS for the full year 2024 of $15.00 to $16.00. It expects total revenue to decline by a low- to mid-single digit percentage versus 2023 and operating income to grow by a low-double digit percentage, and it assumed that foreign exchange rates as of February 9, 2024 will remain in effect for the rest of the year.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…